• Danya Reich
  • Corinna Eleni Psomadakis
  • Bobby Buka


Pompholyx, or dyshidrotic eczema, is a chronic dermatitis that mainly affects the hands and, less frequently, the feet. The condition causes highly pruritic vesicles to form on the palms and lateral aspects of the fingers, with some individuals experiencing a burning sensation. The etiology of pompholyx is thought to be multifactorial and is known to be exacerbated by a number of factors, including emotional stress, smoking, contact allergies, eczema, and compromised immune state. Treatment of pompholyx should aim to limit any known causal factors as well as address the inflammation seen in acute flares. Potent topical corticosteroids are first-line treatment. Individuals who do not respond to topical corticosteroids may be treated with a topical immunomodulators such as tacrolimus. The condition tends to be chronic and recurrent.


Dyshidrotic eczema Eczema Pompholyx Hand eczema Vesicles Vesicular dermatitis Chronic Topical steroid Corticosteroid Prednisone Phototherapy 


  1. 1.
    Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2010;11(5):305–14.CrossRefGoogle Scholar
  2. 2.
    Guillet MH, Wierzbicka E, Guillet S, Dagregorio G, Guillet G. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol. 2007;143(12):1504–8.CrossRefGoogle Scholar
  3. 3.
    Letić M. Use of sunglight to treat dyshidrotic eczema. JAMA Dermatol. 2013;149(5):634–5.CrossRefGoogle Scholar
  4. 4.
    Lee KC, Ladizinski B. Dyshidrotic eczema following intravenous immunoglobullin treatment. CMAJ. 2013;185(11):E530.CrossRefGoogle Scholar
  5. 5.
    Doshi DN, Cheng CE, Kimball AB. Chapter 16. Vesicular palmoplantar eczema. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. Available from: Accessed 18 Nov 2014.Google Scholar
  6. 6.
    Sehgal VN, Srivastava G, Aggarwal AK, Sharma AD. Hand dermatitis/eczema: current management strategy. J Dermatol. 2010;37(7):593–610.CrossRefGoogle Scholar
  7. 7.
    Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82(3):249–55. Review.PubMedGoogle Scholar
  8. 8.
    Kotan D, Erdem T, Acar BA, Boluk A. Dyshidrotic eczema associated with the use of IVIg. BMJ Case Rep. 2013. doi: 10.1136/bcr-2012-008001.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142(2):213–7.CrossRefGoogle Scholar
  10. 10.
    Miyamoto J, Böckle BC, Zillikens D, Schmidt E, Schmuth M. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. JAMA Dermatol. 2014;150(10):1120–2.CrossRefGoogle Scholar
  11. 11.
    Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999;40(4):612–4.CrossRefGoogle Scholar
  12. 12.
    Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002;16(1):40–2.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Danya Reich
    • 1
  • Corinna Eleni Psomadakis
    • 2
  • Bobby Buka
    • 3
  1. 1.Department of Family MedicineMount Sinai School of Medicine Attending Mount Sinai Doctors/Beth Israel Medical Group-WilliamsburgBrooklynUSA
  2. 2.School of Medicine Imperial College LondonLondonUK
  3. 3.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations